Actinium Pharmaceuticals (NYSE:ATNM) versus ProMetic Life Sciences (OTCMKTS:PFSCF) Financial Contrast

ProMetic Life Sciences (OTCMKTS:PFSCF) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Volatility & Risk

ProMetic Life Sciences has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.

Profitability

This table compares ProMetic Life Sciences and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Insider & Institutional Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares ProMetic Life Sciences and Actinium Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A
Actinium Pharmaceuticals	$90,000.00	467.94	-$48.82 million	($1.10)	-1.23

Actinium Pharmaceuticals has lower revenue, but higher earnings than ProMetic Life Sciences.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ProMetic Life Sciences and Actinium Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMetic Life Sciences	0	0	0	0	0.00
Actinium Pharmaceuticals	0	0	1	0	3.00

Actinium Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 196.30%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than ProMetic Life Sciences.

Summary

Actinium Pharmaceuticals beats ProMetic Life Sciences on 10 of the 12 factors compared between the two stocks.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.